Diligence memo · auto-generated · as of July 3, 2026
Oisin Biotechnologies, Inc.
Oisin Biotechnologies, Inc. looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
Oisin Biotechnologies, Inc. operates in Biotech / Pharma, based in SEATTLE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Oisin Biotechnologies, Inc. has raised $18M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $9.5M on 2020-06-10.
Most recent recorded round closed around 2024-06-28.
Valuation (modeled)modeled
Provath models Oisin Biotechnologies, Inc. at approximately $28M (range $6.0M–$61M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.72× the median modeled value of Series A Biotech / Pharma companies in 2022–2024 (21 peers) — value vs value, same stage and era. Within the normal band (72% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 20 months.
Last raise 2.0 yr ago; this sector typically re-raises about every 15 months.
Slightly overdue versus sector cadence.
The last round stepped up 11.3× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 75% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 52% of those peers.
Closest niche peers: Laxmi Therapeutic Devices, Inc., Accipiter Biosciences Inc., Nanospectra Biosciences Inc, Ten Bay Bio, Inc., Genomic Life, Inc..
Peoplefiled
8 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.